Abiopharma

🔍 Kung Winston (Executive)

Company: Janux Therapeutics, Inc. (JANX)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Common Stock (Direct)
  Date: 2026-06-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,750.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 15,500 shares of Stock Option (right to buy) at $13.66 per share (Derivative)
  Date: 2026-06-11 | Code: A | Expires: 2036-06-10 | equity_swap_involved: 0 | shares_owned_after: 15,500.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
• F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.